Zydus Lifesciences Q1 FY27 Revenue Up 22% to ₹80,170 Mn
Zydus Lifesciences reported a 22% year-on-year increase in revenue from operations to ₹80,170 million for the first quarter of FY27, ending June 30, 2026. Despite the revenue growth, EBITDA saw an 8% decline to ₹19,294 million, and Net Profit decreased by 36% to ₹9,398 million compared to the previous year. R&D investments stood at 8% of revenues. The company highlighted strong performance in its branded portfolio, which now exceeds 55% of revenues, with significant contributions from the US market. Key business segments like Pharma and Consumer Wellness showed growth, although North America Formulations experienced a slight dip. The company also completed the acquisition of Assertio Holdings, strengthening its US specialty presence.
Key Highlights
- Revenue from operations surged 22% YoY to ₹80,170 million.
- Net Profit declined 36% YoY to ₹9,398 million.
- EBITDA decreased 8% YoY to ₹19,294 million.
- Branded portfolio now constitutes over 55% of total revenues.
- Acquisition of Assertio Holdings completed, boosting US specialty presence.
Price Impact
More from ZYDUSLIFE